Skip to content

Study · Randomized controlled trial · 2026

3 results

Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.

Sattar N, Gerstein HC, D'Alessio D, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Zinman B and 9 more

Show all authors

Zoungas S, Bartee A, Miller D, Nishiyama H, Qu Y, Weerakkody G, Wiese RJ, Pavo I, Nicholls SJ

Diabetes care1 Oct 2026Cited by 8 (Europe PMC)

PMID41940793 (opens in a new tab)PMCIDPMC13594787 (opens in a new tab)DOI10.2337/dc26-0298 (opens in a new tab)PepBankPUB-41940793
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide compared with imputed placebo was associated with lower MACE-3 (HR 0.72; 95% CI 0.55, 0.94).

    In plain wordsIn adults with type 2 diabetes and heart disease, tirzepatide was linked to fewer major cardiovascular events than an estimated placebo, in an indirect comparison.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMACE-3
    Study

    n: not reported in source

    Comparator
    Imputed placebo
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.72 ratio
    MACE-3

    Source sentences

    Summary
    tirzepatide versus placebo was associated with lower MACE-3 (HR 0.72; 95% CI 0.55, 0.94)
    1 context sentence
    Summary · context
    In prespecified analyses, the treatment effect for major adverse cardiovascular event (MACE) of tirzepatide compared with imputed placebo was estimated using SURPASS-Cardiovascular Outcomes Trial (SURPASS-CVOT) and Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial data.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In an indirect comparison, tirzepatide versus imputed placebo was associated with fewer deaths from cardiovascular cause or heart failure events (HR 0.70; 95% CI 0.51, 0.96).

    In plain wordsIn an indirect comparison, tirzepatide was linked to fewer cardiovascular deaths or heart failure events than an estimated placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseDeath from CV cause or heart failure events
    Study

    n: not reported in source

    Comparator
    Imputed placebo
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.7 ratio
    death from CV cause or heart failure events

    Source sentences

    Summary
    death from CV cause or heart failure events (HR 0.70; 95% CI 0.51, 0.96)
    1 context sentence
    Summary · context
    In prespecified analyses, the treatment effect for major adverse cardiovascular event (MACE) of tirzepatide compared with imputed placebo was estimated using SURPASS-Cardiovascular Outcomes Trial (SURPASS-CVOT) and Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial data.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In an indirect comparison, tirzepatide versus imputed placebo was associated with lower all-cause death (HR 0.61; 95% CI 0.45, 0.82).

    In plain wordsIn an indirect comparison, tirzepatide was linked to fewer deaths from any cause than an estimated placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause death
    Study

    n: not reported in source

    Comparator
    Imputed placebo
    Analysis
    Secondary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.61 ratio
    all-cause death

    Source sentences

    Summary
    all-cause death (HR 0.61; 95% CI 0.45, 0.82)
    1 context sentence
    Summary · context
    In prespecified analyses, the treatment effect for major adverse cardiovascular event (MACE) of tirzepatide compared with imputed placebo was estimated using SURPASS-Cardiovascular Outcomes Trial (SURPASS-CVOT) and Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial data.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 8Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.